Enhanced immune responses and protection by vaccination with respiratory syncytial virus fusion protein formulated with CpG oligodeoxynucleotide and innate defense regulator peptide in polyphosphazene microparticles

Vaccine

Volumn 30, Issue 35, 2012, Pages 5206-5214

  Garlapati, S ^a   Garg, R ^a   Brownlie, R ^a   Latimer, L ^a   Simko, E ^b   Hancock, R E W ^c   Babiuk, L A ^d   Gerdts, V ^a,b   Potter, A ^a,b   van Drunen Littel van den Hurk, S ^a,b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Polyphosphazene microparticles; Protection; RSV fusion protein

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; EOTAXIN; GAMMA INTERFERON; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G ANTIBODY; INNATE DEFENSE REGULATOR PEPTIDE; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; NEUTRALIZING ANTIBODY; PEPTIDE; POLYMER; POLYPHOSPHAZENE; RECOMBINANT VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; SUBUNIT VACCINE; UNCLASSIFIED DRUG; VIRUS FUSION PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOPATHOLOGY; LOEFFLER PNEUMONIA; LUNG LAVAGE; MAMMAL CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PARAMYXOVIRUS INFECTION; PARTICLE SIZE; PRIORITY JOURNAL; PROTECTION; PROTEIN ANALYSIS; PROTEIN PURIFICATION; RAT; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VACCINATION; VIRUS NEUTRALIZATION; VIRUS PNEUMONIA; VIRUS REPLICATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; BRONCHOALVEOLAR LAVAGE FLUID; CELL LINE; FEMALE; HUMANS; IMMUNITY, INNATE; IMMUNOGLOBULIN E; INTERLEUKIN-13; INTERLEUKIN-4; INTERLEUKIN-5; LUNG; MICE; MICE, INBRED BALB C; OLIGODEOXYRIBONUCLEOTIDES; ORGANOPHOSPHORUS COMPOUNDS; POLYMERS; RATS; RECOMBINANT PROTEINS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUSES; VACCINATION; VIRAL FUSION PROTEINS; VIRUS REPLICATION;

EID: 84863815619     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.06.011     Document Type: Article

References (40)

1. Shay D.K., Holman R.C., Roosevelt G.E., Clarke M.J., Anderson L.J. Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997. J Infect Dis 2001, 183(January (1)):16-22.
2. Van Drunen Littel-van den Hurk S., Watkiss E. Pathogenesis of respiratory syncytial virus. Curr Opin Virol 2012, 2:1-6.
3. Falsey A.R., Hennessey P.A., Formica M.A., Cox C., Walsh E.E. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005, 352(17):1749-1759.
4. Kim H.W., Canchola J.G., Brandt C.D., Pyles G., Chanock R.M., Jensen K., et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969, 89(April (4)):422-434.
5. Collins P.L., Graham B.S. Viral and host factors in human respiratory syncytial virus pathogenesis. J Virol 2008, 82(March (5)):2040-2055.
6. O'Hagan D.T., De Gregorio E. The path to a successful vaccine adjuvant-'the long and winding road'. Drug Discov Today 2009, 14(Jun (11-12)):541-551.
7. Delgado M.F., Coviello S., Monsalvo A.C., Melendi G.A., Hernandez J.Z., Batalle J.P., et al. Lack of antibody affinity maturation due to poor toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med 2009, 15(January (1)):34-41.
8. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002, 20:709-760.
9. Kovacs-Nolan J., Latimer L., Landi A., Jenssen H., Hancock R.E., Babiuk L.A., et al. The novel adjuvant combination of CpG ODN, indolicidin and polyphosphazene induces potent antibody- and cell-mediated immune responses in mice. Vaccine 2009, 27(March (14)):2055-2064.
10. Kovacs-Nolan J., Mapletoft J.W., Latimer L., Babiuk L.A., Hurk S.D. CpG oligonucleotide, host defense peptide and polyphosphazene act synergistically, inducing long-lasting, balanced immune responses in cattle. Vaccine 2009, 27(March (14)):2048-2054.
11. Kovacs-Nolan J., Mapletoft J.W., Lawman Z., Babiuk L.A., van Drunen Littel-van den Hurk S. Formulation of bovine respiratory syncytial virus fusion protein with CpG oligodeoxynucleotide, cationic host defence peptide and polyphosphazene enhances humoral and cellular responses and induces a protective type 1 immune response in mice. J Gen Virol 2009, 90(August (Pt. 8)):1892-1905.
12. Kindrachuk J., Jenssen H., Elliott M., Townsend R., Nijnik A., Lee S.F., et al. A novel vaccine adjuvant comprised of a synthetic innate defence regulator peptide and CpG oligonucleotide links innate and adaptive immunity. Vaccine 2009, 27(July (34)):4662-4671.
13. Oumouna M., Mapletoft J.W., Karvonen B.C., Babiuk L.A., van Drunen Littel-van den Hurk S. Formulation with CpG oligodeoxynucleotides prevents induction of pulmonary immunopathology following priming with formalin-inactivated or commercial killed bovine respiratory syncytial virus vaccine. J Virol 2005, 79(February (4)):2024-2032.
14. Krishnamachari Y., Salem A.K. Innovative strategies for co-delivering antigens and CpG oligonucleotides. Adv Drug Deliv Rev 2009, 61(March (3)):205-217.
15. Yeung A., Gellatly S., Hancock R. Multifunctional cationic host defence peptides and their clinical applications. Cell Mol Life Sci 2011, 1-16.
16. Nijnik A., Madera L., Ma S., Waldbrook M., Elliott M.R., Easton D.M., et al. Synthetic cationic peptide IDR-1002 provides protection against bacterial infections through chemokine induction and enhanced leukocyte recruitment. J Immunol 2010, 184(March (5)):2539-2550.
17. Andrianov A.K., DeCollibus D.P., Gillis H.A., Kha H.H., Marin A., Prausnitz M.R., et al. Poly[di(carboxylatophenoxy)phosphazene] is a potent adjuvant for intradermal immunization. Proc Natl Acad Sci USA 2009, 106(November (45)):18936-18941.
18. Garlapati S., Eng N.F., Wilson H.L., Buchanan R., Mutwiri G.K., Babiuk L.A., et al. PCPP (poly[di(carboxylatophenoxy)-phosphazene]) microparticles co-encapsulating ovalbumin and CpG oligo-deoxynucleotides are potent enhancers of antigen specific Th1 immune responses in mice. Vaccine 2010, 29(December (38)):6540-6548.
19. Garlapati S., Eng N.F., Wilson H.L., Buchanan R., Mutwiri G.K., Babiuk L.A., et al. PCPP (poly[di(carboxylatophenoxy)-phosphazene]) microparticles co-encapsulating ovalbumin and CpG oligo-deoxynucleotides are potent enhancers of antigen specific Th1 immune responses in mice. Vaccine 2011, 28(September (52)):8306-8314.
20. Mapletoft J.W., Oumouna M., Kovacs-Nolan J., Latimer L., Mutwiri G., Babiuk L.A., et al. Intranasal immunization of mice with a formalin-inactivated bovine respiratory syncytial virus vaccine co-formulated with CpG oligodeoxynucleotides and polyphosphazenes results in enhanced protection. J Gen Virol 2008, 89(January (Pt. 1)):250-260.
21. Ternette N., Stefanou D., Kuate S., Uberla K., Grunwald T. Expression of RNA virus proteins by RNA polymerase II dependent expression plasmids is hindered at multiple steps. Virol J 2007, 4:51.
22. Mapletoft J.W., Oumouna M., Kovacs-Nolan J., Latimer L., Mutwiri G., Babiuk L.A., et al. Intranasal immunization of mice with a formalin-inactivated bovine respiratory syncytial virus vaccine co-formulated with CpG oligodeoxynucleotides and polyphosphazenes results in enhanced protection. J Gen Virol 2008, 89(January (1)):250-260.
23. Prince G.A., Prieels J.P., Slaoui M., Porter D.D. Pulmonary lesions in primary respiratory syncytial virus infection, reinfection, and vaccine-enhanced disease in the cotton rat (Sigmodon hispidus). Lab Invest: J Tech Methods Pathol 1999, 79(November (11)):1385-1392.
24. Graham B.S. Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol Rev 2011, 239(January (1)):149-166.
25. Singh S.R., Dennis V.A., Carter C.L., Pillai S.R., Jefferson A., Sahi S.V., et al. Immunogenicity and efficacy of recombinant RSV-F vaccine in a mouse model. Vaccine 2007, 25(August (33)):6211-6223.
26. Swanson K.A., Settembre E.C., Shaw C.A., Dey A.K., Rappuoli R., Mandl C.W., et al. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc Natl Acad Sci USA 2011, 108(June (23)):9619-9624.
27. Prince G.A., Capiau C., Deschamps M., Fabry L., Garcon N., Gheysen D., et al. Efficacy and safety studies of a recombinant chimeric respiratory syncytial virus FG glycoprotein vaccine in cotton rats. J Virol 2000, 74(November (22)):10287-10292.
28. Hancock G.E., Heers K.M., Smith J.D., Scheuer C.A., Ibraghimov A.R., Pryharski K.S. CpG containing oligodeoxynucleotides are potent adjuvants for parenteral vaccination with the fusion (F) protein of respiratory syncytial virus (RSV). Vaccine 2001, 19(September (32)):4874-4882.
29. Shafique M., Wilschut J., de Haan A. Induction of mucosal and systemic immunity against respiratory syncytial virus by inactivated virus supplemented with TLR9 and NOD2 ligands. Vaccine 2012, 30(January (3)):597-606.
30. Amidi M., Mastrobattista E., Jiskoot W., Hennink W.E. Chitosan-based delivery systems for protein therapeutics and antigens. Adv Drug Deliv Rev 2010, 62(1):59-82.
31. Mutwiri G., Gerdts V., van Drunen Littel-van den Hurk S., Auray G., Eng N., Garlapati S., et al. Combination adjuvants: the next generation of adjuvants?. Expert Rev Vaccines 2011, 10(January (1)):95-107.
32. Adair B.M. Nanoparticle vaccines against respiratory viruses. Wiley Interdiscip Rev 2009, 1(July-August (4)):405-414.
33. Nallet S., Amacker M., Westerfeld N., Baldi L., Konig I., Hacker D.L., et al. Respiratory syncytial virus subunit vaccine based on a recombinant fusion protein expressed transiently in mammalian cells. Vaccine 2009, 27(October (46)):6415-6419.
34. Lindell D.M., Morris S.B., White M.P., Kallal L.E., Lundy P.K., Hamouda T., et al. A novel inactivated intranasal respiratory syncytial virus vaccine promotes viral clearance without Th2 associated vaccine-enhanced disease. PloS One 2011, 6(7):e21823.
35. Levy O., Zarember K.A., Roy R.M., Cywes C., Godowski P.J., Wessels M.R. Selective impairment of TLR-mediated innate immunity in human newborns: neonatal blood plasma reduces monocyte TNF-alpha induction by bacterial lipopeptides, lipopolysaccharide, and imiquimod, but preserves the response to R-848. J Immunol 2004, 173(October (7)):4627-4634.
36. Abulencia A., Acosta D., Adelman J., Affolder T., Akimoto T., Albrow M.G., et al. Measurement of the Bc+ meson lifetime using the decay mode Bc+→J/Psie+nue. Phys Rev Lett 2006, 97(July (1)):012002.
37. Weeratna R.D., Brazolot Millan C.L., McCluskie M.J., Davis H.L. CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice. FEMS Immunol Med Microbiol 2001, 32(1):65-71.
38. Philbin V.J., Dowling D.J., Gallington L.C., Cortes G., Tan Z., Suter E.E., et al. Imidazoquinoline toll-like receptor 8 agonists activate human newborn monocytes and dendritic cells through adenosine-refractory and caspase-1-dependent pathways. J Allergy Clin Immunol 2012, (April).
39. Gracia A., Polewicz M., Halperin S.A., Hancock R.E., Potter A.A., Babiuk L.A., et al. Antibody responses in adult and neonatal BALB/c mice to immunization with novel Bordetella pertussis vaccine formulations. Vaccine 2011, 29(February (8)):1595-1604.
40. Wilson H.L., Kovacs-Nolan J., Latimer L., Buchanan R., Gomis S., Babiuk L., et al. A novel triple adjuvant formulation promotes strong, Th1-biased immune responses and significant antigen retention at the site of injection. Vaccine 2010, 28(December (52)):8288-8299.